Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 6/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | GUSB | P08236 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511616 | 0.85 | ALDH1A1 (0.68) | TNKSTNKS2CYP1A1CYP1B1MAPT | |
| SCHEMBL4497130 | 0.85 | KDM4E (0.52) | TNKSTNKS2CYP1A1CYP1B1MAPT | |
| SCHEMBL4510483 | 0.85 | MAPT (0.52) | TNKSTNKS2CYP1A1CYP1B1MAPT | |
| SCHEMBL4509131 | 0.85 | TNKS2 (0.58) | TNKSTNKS2MAPTALDH1A1KDM4E | |
| SCHEMBL4509994 | 0.85 | GUSB (0.60) | TNKSTNKS2CYP1A1CYP1B1MAPT | |
| SCHEMBL4510141 | 0.82 | GUSB (0.60) | TNKSTNKS2CYP1A1CYP1B1MAPT | |
| SCHEMBL4508296 | 0.75 | GUSB (0.60) | TNKSTNKS2CYP1A1CYP1B1MAPT | |
| SCHEMBL29784068 | 0.74 | TNKS (1.00) | TNKSTNKS2CYP1A1CYP1B1MAPT | |
| SCHEMBL5795292 | 0.74 | TNKS (1.00) | TNKSTNKS2CYP1A1CYP1B1MAPT | |
| SCHEMBL4501935 | 0.74 | KDM4E (0.53) | TNKSTNKS2MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | claimed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | TNKS 116/4885TNKS2 78/4885CYP1A1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.